Visgenx, Inc
Visgenx, Inc., based in Santa Cruz, CA, is focused on developing innovative gene therapies for degenerative retinal diseases, particularly targeting dry age-related macular degeneration (Dry AMD). The company is pioneering therapeutics that aim to increase the expression of the ELOVL2 gene, which is believed to play a crucial role in regulating aging in the retina and other tissues.
With a dedicated team of scientists, entrepreneurs, and drug developers, Visgenx is committed to creating treatments that can slow or halt cellular senescence associated with macular degeneration and other age-related disorders. Their research emphasizes the importance of lipid fatty acid biosynthesis and its connection to the declining expression of ELOVL2 in the progression of Dry AMD.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.